DE69727956D1 - Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen - Google Patents

Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen

Info

Publication number
DE69727956D1
DE69727956D1 DE69727956T DE69727956T DE69727956D1 DE 69727956 D1 DE69727956 D1 DE 69727956D1 DE 69727956 T DE69727956 T DE 69727956T DE 69727956 T DE69727956 T DE 69727956T DE 69727956 D1 DE69727956 D1 DE 69727956D1
Authority
DE
Germany
Prior art keywords
depressions
pharmaceutical preparations
reducing breathing
reducing
breathing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69727956T
Other languages
English (en)
Inventor
Kwen-Jen Chang
Robert W Mcnutt
Hugh O Pettit
Michael J Bishop
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ardent Pharmaceuticals Inc
Original Assignee
Ardent Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ardent Pharmaceuticals Inc filed Critical Ardent Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69727956D1 publication Critical patent/DE69727956D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DE69727956T 1996-06-05 1997-05-28 Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen Expired - Lifetime DE69727956D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/658,726 US5807858A (en) 1996-06-05 1996-06-05 Compositions and methods for reducing respiratory depression
PCT/US1997/009123 WO1997046240A1 (en) 1996-06-05 1997-05-28 Compositions and methods for reducing respiratory depression

Publications (1)

Publication Number Publication Date
DE69727956D1 true DE69727956D1 (de) 2004-04-08

Family

ID=24642427

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69727956T Expired - Lifetime DE69727956D1 (de) 1996-06-05 1997-05-28 Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen

Country Status (7)

Country Link
US (1) US5807858A (de)
EP (1) EP0938317B1 (de)
AT (1) ATE260658T1 (de)
AU (1) AU714472B2 (de)
CA (1) CA2257393C (de)
DE (1) DE69727956D1 (de)
WO (1) WO1997046240A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985880A (en) 1996-06-05 1999-11-16 Delta Pharmaceuticals Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
SE9504661D0 (sv) 1995-12-22 1995-12-22 Astra Pharma Inc New compounds
GB9709972D0 (en) * 1997-05-19 1997-07-09 Pfizer Ltd Tetrazoles
WO1999065932A1 (en) 1998-06-18 1999-12-23 Sepracor, Inc. Tetrapeptides, analogs and peptidomimetics which bind selectively mammalian opioid receptors
SE9904673D0 (sv) 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
SE9904674D0 (sv) 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
US7115664B2 (en) 2000-03-16 2006-10-03 Sepracor Inc. Peptidomimetic ligands for cellular receptors and ion channels
SE0001209D0 (sv) 2000-04-04 2000-04-04 Astrazeneca Canada Inc Novel compounds
PT1395567E (pt) * 2001-05-18 2009-03-26 Astrazeneca Ab Derivados de 4(fenil-piperazinil-metil)benzamida e sua utilização para o tratamento da ansiedade da dor ou de distúrbios gastrointestinais
NZ531875A (en) * 2001-09-25 2006-10-27 Ardent Pharmaceuticals Inc An enantiomerically pure diarylmethylpiperazine and methods for use in the treatment for conditions such as drug addiction, mental disorders, arthritis and asthma
US7189725B2 (en) * 2001-09-25 2007-03-13 Mount Cook Biosciences, Inc. Enantiomerically pure opioid diarylmethylpiperazine as a cardioprotection agent
US7355042B2 (en) * 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
US7030124B2 (en) * 2001-10-29 2006-04-18 Ardent Pharmaceuticals, Inc. Method of treating depression with delta receptor agonist compounds
AU2003214800A1 (en) 2002-01-02 2003-07-24 Ardent Pharmaceuticals, Inc. Method of treating sexual dysfunctions with delta opioid receptor agonist compounds
US8476280B2 (en) * 2002-05-09 2013-07-02 Versi Group, Llc Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists
SE0203302D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203303D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203300D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
US7314880B2 (en) * 2003-01-02 2008-01-01 Mount Cook Biosciences, Inc. Cardioprotective delta opioid receptor agonists and methods of using same
US20070099957A1 (en) * 2003-05-16 2007-05-03 Astra Zeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
SE0400027D0 (sv) * 2004-01-09 2004-01-09 Astrazeneca Ab Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
MX2007001240A (es) * 2004-08-02 2007-03-23 Astrazeneca Ab Derivados de diarilmetil-piperazina, preparaciones y usos de las mismas.
SE0401968D0 (sv) * 2004-08-02 2004-08-02 Astrazeneca Ab Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
JP2008546638A (ja) * 2005-04-14 2008-12-25 マウント クック バイオサイエンシズ，インコーポレイテッド 新規なオピオイド化合物の組成物およびその使用方法
US20070197786A1 (en) * 2005-07-22 2007-08-23 Kwen-Jen Chang Enantiomerically pure opioid diarylmethylpiperazine
AU2007265467C1 (en) 2006-06-28 2013-11-07 Amgen Inc. Glycine transporter-1 inhibitors
AU2009249714A1 (en) * 2008-05-20 2009-11-26 Astrazeneca Ab Method of treating anxious major depressive disorder
US11246865B2 (en) * 2017-04-30 2022-02-15 Versi Group, Llc Opioid for use to reduce and/or treat drug addiction

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2630435A (en) * 1948-09-09 1953-03-03 Burroughs Wellcome Co N-benzohydryl-n-methyl piperazines and process of preparing same
US4518711A (en) * 1983-05-16 1985-05-21 Gibson-Stephens Institute Conformationally constrained cyclic enkephalin analogs with delta receptor specificity
GB8320701D0 (en) * 1983-08-01 1983-09-01 Wellcome Found Chemotherapeutic agent
IL78939A (en) * 1986-01-17 1990-04-29 Robins Co Inc A H Pharmaceutical compositions containing n-substituted arylalkyl-and arylalkylene-piperidines and tetrahydropyridines and certain such novel compounds
EP0287339B1 (de) * 1987-04-16 1994-08-17 Eli Lilly And Company Piperidine als Opioid-Antagoniste
US4816586A (en) * 1987-07-29 1989-03-28 Regents Of The University Of Minnesota Delta opioid receptor antagonists
WO1990015599A1 (en) * 1989-06-19 1990-12-27 The Wellcome Foundation Limited Medicaments useful in cancer therapy and having antihistaminic properties
EP0458160A3 (en) * 1990-05-25 1992-03-18 Sociedad Espanola De Especialidades Farmaco-Terapeuticas, S.A. Substituted diphenylmethane derivatives as analgesic or anti-inflammatory agents
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
IE914218A1 (en) * 1991-09-11 1993-03-24 Mcneilab Inc Novel 4-arylpiperazines and 4-arylpiperidines
US5574159A (en) * 1992-02-03 1996-11-12 Delta Pharmaceuticals, Inc. Opioid compounds and methods for making therefor
GB9202238D0 (en) * 1992-02-03 1992-03-18 Wellcome Found Compounds
RU2133744C1 (ru) * 1993-07-30 1999-07-27 Дельта Фармасьютикалз, Инк. Пиперазиновые соединения

Also Published As

Publication number Publication date
AU714472B2 (en) 2000-01-06
ATE260658T1 (de) 2004-03-15
EP0938317A4 (de) 2000-08-23
EP0938317A1 (de) 1999-09-01
AU3079897A (en) 1998-01-05
EP0938317B1 (de) 2004-03-03
CA2257393A1 (en) 1997-12-11
WO1997046240A1 (en) 1997-12-11
US5807858A (en) 1998-09-15
CA2257393C (en) 2010-08-24

Similar Documents

Publication Publication Date Title
DE69727956D1 (de) Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen
ATE231519T1 (de) Dinukleotide zur verwendung in der behandlung von lungenkrankheiten
MY123354A (en) 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
NO971889D0 (no) Forbindelser og sammensetninger for levering av aktive midler
SE9504661D0 (sv) New compounds
DK0889875T3 (da) Cycloproylalkansyrederivater
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
AP9801378A0 (en) 9-amino-3- keto erythromycin derivatives.
DE69637050D1 (de) Verwendung von n-substituierten pyridonen als tumornekrose-faktor alpha hemmer
EP1140900A4 (de) Pyrazol verbindungen und ihre verwendung
FI972434A0 (fi) Lamotrigiiniä sisältävä farmaseuttinen koostumus
ES2108595A1 (es) Derivados de la 3(2h)-piridacinona y procedimiento para su preparacion.
FI934680A (fi) Arylmorfolin, framstaellning och anvaending
ATE246515T1 (de) Verfahren zur herstellung von oralen dosierungsformulierungen enthaltend diclofenac
DK0823909T3 (da) Hidtil ukendte heterocykliske forbindelser
DK0866711T3 (da) Anvendelse af 6-methyl-5-oxo-3-thiomorpholinylcarbonyl-L-histidyl-L-prolinamid til fremstilling af et farmaceutisk præparat til modvirkning af sövnapnö
DE69330601D1 (de) Serotoninergische ergolin derivate
SE9504662D0 (sv) New compounds
GR3032950T3 (en) Substituted fused and bridged bicyclic compounds as therapeutic agents
AP9801235A0 (en) Erythromycin derivatives.
MY133438A (en) Morpholinobenzamide salts
NO950177L (no) Farmakologisk aktive erivater
DK0802920T3 (da) Fusacandin-antisvampemidler
MX9701528A (es) Derivados de 1, 1, 2,- trifenilbut-1-eno para tratar la enfermedad de alzheimer.

Legal Events

Date Code Title Description
8332 No legal effect for de